Filing Flows › Comparisons › SBFM vs RCUS
Sunshine Biopharma vs Arcus Biosciences: SBFM and RCUS compared
Sunshine Biopharma is the larger company: $9.3M of revenue in its latest quarter (Q2 2026) against $9.0M for Arcus Biosciences (Q3 2026). Sunshine Biopharma is growing faster (-2% against -65% a year earlier).
Where the money goes: SBFM and RCUS
Sunshine Biopharma (SBFM) · Q2 2026
Sunshine Biopharma, Q2 2026: revenue $9.3M (-2% year over year), operating margin -17.4%, net loss $1.6M, operating cash flow −$918K. The chart follows the revenue to costs, profit and cash.
Arcus Biosciences (RCUS) · Q3 2026
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
| Sunshine Biopharma (SBFM) | Arcus Biosciences (RCUS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $9.3M | $9.0M |
| Revenue growth, Y/Y | -2% | -65% |
| Operating margin | -17.4% | n/m |
| Net earnings | −$1.6M | −$128M |
| Net margin | -16.9% | — |
| Operating cash flow | −$918K | −$88.0M |
Where the revenue comes from
Arcus Biosciences
- License and development services: $8.0M (89%)
- Other collaboration: $1.0M (11%)
Questions
Which is bigger, Sunshine Biopharma or Arcus Biosciences?
Sunshine Biopharma is the larger company: $9.3M of revenue in its latest quarter (Q2 2026) against $9.0M for Arcus Biosciences (Q3 2026).
Is Sunshine Biopharma or Arcus Biosciences growing faster?
Sunshine Biopharma is growing faster (-2% against -65% a year earlier).
More: Sunshine Biopharma earnings · how Sunshine Biopharma makes money · Arcus Biosciences earnings · how Arcus Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.